As Eli Lilly and Co. celebrates its past, CEO David Ricks is also focusing on the future of the company. This week, the Indianapolis-based drugmaker is marking 150 years since Col. Eli Lilly founded ...

Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing ...

There's no question Eli Lilly has been the most active biopharma dealmaker of recent months, but even the billions the pharma already spent on acquisitions hasn't exhausted its appetite. The latest ...

In 1876, Alexander Graham Bell received the patent for the telephone, William McKinley was elected president of the United States and Colorado became the country's 38th state. That same year, on May ...

INDIANAPOLIS — Scientists in Indianapolis working for Eli Lilly are developing new treatments for cancer and diabetes, and the company is marking its 150th year in medicine with a ceremony downtown ...

Eli Lilly trades at $948.45 as of writing. Our 24/7 Wall St. price target is $1,085 over the next 12 months, implying roughly 14.3% upside. The recommendation is buy with a confidence level of 70%.

Eli Lilly's work in diabetes and weight loss is doing most of the heavy lifting right now. The company's financial results have been outstanding thanks to its dominance in the anti-obesity market. But ...

Eli Lilly on May 21 said its experimental weight-loss shot retatrutide delivered dramatic weight loss in a late-stage study of people with obesity. Lilly said people on the next-generation weight loss ...

Eli Lilly (NYSE:LLY | LLY Price Prediction) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B (+80%). CEO ...

Flashy 3-pointers. Top athletes playing under the lights. Cameras zooming in on a celebrity making a game-winning shot. Those are the kinds of scenes you’d typically associate with a Big Pharma ad ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

WASHINGTON, May 18 (Reuters) - The U.S. Supreme Court declined on Monday to hear a challenge by drugmaker Eli Lilly (LLY.N), opens new tab to a Civil War-era whistleblower law that has recovered ...